metamorworks
A number of medtech firms are anticipated to launch monetary updates or different company information this coming week when the massive annual JP Morgan Healthcare Convention convenes in San Francisco.
Canaccord Genuity mentioned in a latest observe that it’s anticipating ten of the businesses it covers within the diagnostics and instruments house to be making shows this week: 10x Genomics (TXG), Precise Sciences (NASDAQ:EXAS), Guardant Well being (NASDAQ:GH), Illumina (NASDAQ:ILMN), Natera (NTRA), Pacific Biosciences (NASDAQ:PACB), NanoString Applied sciences (NASDAQ:NSTG), Akoya Biosciences (NASDAQ:AKYA) and Quanterix (NASDAQ:QTRX).
Among the many firms slated to current this week, Akoya, Precise Sciences, NanoString and Pacific Biosciences are seen as most definitely to preannounce preliminary This autumn 2023 monetary outcomes, with Quanterix, Illumina and Guardant additionally seen as prospects. Unlikely to preannounce are 10x Genomics and Natera, Canaccord mentioned.
The funding agency would not suppose any of these firms will roll out 2024 steerage this week. It additionally doesn’t see Illumina providing any particulars on the latest departure of its COO or Grail divestiture. It does, nevertheless, see Akoya asserting “at the least one notable non-results growth.”
Canaccord mentioned that commentary from Pacific Biosciences on Revio orders and utilization could be “extremely necessary,” whereas commentary from Guardant on its FDA Advisory Committee assembly for Defend “could be significant.” As for NanoString, “updates on spatial litigation affect and potential money wants are vital.”
Different firms that might probably difficulty updates this week are Biodesix (BDX), Citadel Biosciences (CSTL), Exagen (XGN), Lucid Diagnostics (LUCD), Olink (OLK), SomaLogic (SLGC) and Quantum-Si (QSI), Canaccord added.
Needham, in the meantime, mentioned it expects at the least 13 of the 45 firms its covers medtech and diagnostics house to pre-announce preliminary This autumn earnings by mid-January. The 13 firms are Alphatec (ATEC), AtriCure (ATRC), Axonics (AXNX), Hologic (HOLX), InMode (INMD), Inogen (INGN), Masimo (MASI), OrthoPediatrics (KIDS), Paragon 28 (FNA), Personalis (PSNL), RxSight (RXST), SI-BONE (SIBN) and STAAR Surgical (STAA).
Two different firms, Dentsply Sirona (XRAY) and Sight Sciences (SGHT) may additionally preannounce their preliminary This autumn earnings, Needham added.
Through the January convention season, Needham sees Alphatec and Hologic shares as most definitely to overperform, whereas Masimo shares are the most definitely to underperform as a result of their This autumn preannouncements and/or 2024 steerage.
For Alphatec, Needham sees updates on aggressive rep hires, the sturdiness of PTP’s power and its halo impact on the corporate’s broader portfolio, and the corporate’s capability to proceed enhancing profitability because the three prime subjects that traders will deal with transferring into 2024.
For Hologic, it sees the important thing subjects as being updates on the corporate’s Breast Well being enterprise, diagnostics development drivers reminiscent of Panther utilization, and makes use of of money, reminiscent of inventory buybacks versus M&A.
As for Masimo, Needham expects key subjects for dialogue will likely be any updates on new shopper well being product launches; updates on sensor delays, sensor utilization in 2024 and capital demand; and the corporate’s capability to extend gross and working margins and sources of leverage.
On the sector stage, Needham mentioned it expects macro subjects to dominate convention discussions this 12 months, together with inflation, provide chains, healthcare staffing, forex impacts, capital spending, the financial outlook, GLP-1 weight reduction medication, and the financial scenario in China.
